Esophageal adenocarcinoma: A review and perspectives on the mechanism of carcinogenesis and chemoprevention

Carcinogenesis

Volumn 22, Issue 8, 2001, Pages 1119-1129

  Chen, X ^a   Yang, C S ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ARACHIDONIC ACID; ARACHIDONIC ACID INHIBITOR; CYCLOOXYGENASE 2; ENZYME INHIBITOR; ICOSANOID; IRON; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTEIN P16; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUSTRALIA; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLUMNAR EPITHELIUM; DISEASE EXACERBATION; DUODENUM FLUID; ESOPHAGUS CARCINOMA; ESOPHAGUS INJURY; FRANCE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; INCIDENCE; INFLAMMATION; IRON OVERLOAD; NEW ZEALAND; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRECURSOR; PRIORITY JOURNAL; RAT; REVIEW; RISK FACTOR; SCANDINAVIA; STOMACH JUICE; SWITZERLAND; UNITED KINGDOM; UNITED STATES;

EID: 0034908033     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/22.8.1119     Document Type: Review

References (166)

1. Continuing climb in rates of esophageal adenocarcinoma: An update
2. Barrett's esophagus and esophageal adenocarcinoma
3. Columnar mucosa and intestinal metaplasia of the esophagus
4. Etiology of Barrett's metaplasia and esophageal adenocarcinoma
5. Determinants of survival following the diagnosis of esophageal adenocarcinoma
6. Prognosis of adenocarcinoma arising in Barrett's esophagus
7. A new test gives early warning of a growing killer
8. Management of Barrett's esophagus
9. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
10. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
11. Barrett's esophagus: Does the incidence of adenocarcinoma matter?
12. Epidemiology and molecular biology of Barrett's adenocarcinoma
13. Prevalence of columnarlined (Barrett's) esophagus
14. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus
15. Chronic peptic ulcer of the esophagus and esophagitis
16. Adenocarcinoma of the esophagus in an 8-year-old boy
17. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma
18. Barrett's esophagus, columnar dysplasia and adenocarcinoma of the esophagus
19. The prevalence of Barrett's esophagus in patients with chronic peptic esophageal strictures
20. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
21. Barrett's esophagus: Age, prevalence and extent of columnar epithelium
22. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients
23. Loss of p53 gene increases the incidence of esophageal adenocarcinoma in a surgical model using p53 knockout mice
24. Racial differences in the histology, location and risk factor of esophageal cancer
25. Diet and risk of esophageal cancer by histologic type in a low-risk population
26. Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference
27. Tobacco, alcohol and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
28. Antioxidants and cancers of the esophagus and gastric cardia
29. Risk factors for esophageal cancer in lifelong nonsmokers
30. Effects of en bloc esophagectomy on nutritional and immune status in patients with esophageal carcinoma
31. Association between body mass index and adenocarcinoma of the esophagus and gastric cardia
32. Tobacco, alcohol and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
33. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs and other medications that promote gastroesophageal reflux
34. Rapid progression of Barrett's esophagus to metastatic esophageal carcinoma in a patient with chronic lymphocytic leukemia
35. + strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma
36. The duodenum in gastroesophageal reflux
37. Complications of gastroesophageal reflux disease: Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure and duodenogastric reflux
38. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone
39. Synergism of acid and duo-denogastroesophageal reflux in complicated Barrett's esophagus
40. Induction of esophageal and forestomach carcinoma in rats reflux of duodenal contents
41. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus
42. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction
43. Esophageal adenocarcinoma that probably originated in the esophageal gland duct: A case report
44. Long-term follow-up of Barrett's high-grade dysplasia
45. Barrett's esophagus: Congenital or required
46. Relative importance of biliary and pancreatic secretions in the esophagitis in rats
47. Studies on experimental animals involving surgical procedures and/or nitrosamine treatment related to the etiology of esophageal adenocarcinoma
48. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats
49. Influence of esophagojejunostomy on the induction adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorphine
50. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: An experimental rat model
51. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen
52. Studies of iron deposits, inducible nitric oxide synthase and nitrotyrosine in a rat model for esophageal adenocarcinoma
53. Oxidative damage in an esophageal adenocarcinoma model with rats
54. Esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload
55. Gastrin stimulates epithelial cell proliferation in the esophagus of rats
56. Bile salt induced injury of rabbit esophageal mucosa measured by hydrogen ion disappearance
57. Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus
58. Morphological alteration in experimental esophagitis
59. Long term continuous omeprazole treatment of patients with Barrett's esophagus
60. Proton pump inhibitors for Barrett's esophagus
61. Conservative treatment versus anti-reflux surgery in Barrett's esophagus. Long term results of a prospective study
62. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
63. Gastric juice protects against the development of adenocarcinoma in the rat
64. Is adenocarcinoma following esophagoduodenostomy without carcinogen in the rat reflux-induced?
65. Differentiation and proliferation of Barrett's esophagus and the effects of acid suppression
66. Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion
67. Enhancing effect of bile and bile acid on stomach tumorigenesis induced by N-methyl-N'-nitro-N-nitrosoguanide in Wistar rats
68. Role of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies
69. Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis
70. The etiology of gastric cancer: Intragastric nitrosamide formation and other theories
71. Duodenogastric reflux and foregut carcinogenesis: Analysis of duodenal juice in a rodent model of cancer
72. Potential tumor-promoting activity of bile acids in rat glandular stomach
73. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
74. Activation of the promoters of genes associated with DNA damage, oxidative stress and protein misfolding by the bile salt, deoxycholate
75. Esophagitis in Sprague-Dawley rats is mediated by free radicals
76. Free radical scavengers prevent reflux esophagitis in rats
77. Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats
78. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus
79. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
80. A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma
81. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster
82. High frequency of simultaneous loss of p16 and p16β gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus or stomach
83. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma
84. Expression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) and tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus
85. Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma
86. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region
87. Barrett's esophagus: Microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence
88. Loss of heterozygosity at microsatellite marker sites for tumor suppressor genes in esophageal adenocarcinoma
89. Oncogenes and oncosuppressor gene in adenocarcinoma of the esophagus
90. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer
91. Biomarkers in Barrett's esophagus
92. Molecular biology of Barrett's esophagus and esophageal cancer: Role of p53
93. Recent developments in the molecular characterization of Barrett's esophagus
94. Clinical models of chemoprevention for the esophagus
95. Biomarkers for malignancy in the columnar-lined esophagus
96. Mutations of p53 in Barrett's esophagus and Barrett's cancer: A prospective study of ninety-eight cases
97. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
98. p53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus
99. Expression of p53, PCNA and c-erB-2 in Barrett's metaplasia and adenocarcinoma
100. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis
101. Esophagogastric adenocarcinoma in an E1A/E1B transgenic model involves p53 disruption
102. Evolution of neoplastic cell lineages in Barrett oesophagus
103. Comparative genomic hybridization of cancer of the gastroesophageal junction: Deletion of 14q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinoma
104. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinoma defined using sequence tagged site-amplification mapping quantitative polymerase chain reaction includes the GATA-4 gene
105. Expression profiling using cDNA microarrays
106. Resolution power of two-dimensional electrophoresis and identification of proteins from gels
107. Overexpression of grp94 (glucose-regulated protein 94) in esophageal adenocarcinomas in a surgical rat model and human patients
108. Differential expression of Hsp27 in normal esophagus, Barrett's metaplasia and esophageal adenocarcinomas
109. Aspirin and reduced risk of esophageal carcinoma
110. Aspirin use and risk of fatal cancer
111. An international evaluation of the cancer-preventive potential of non-steroidal anti-inflammatory drugs
112. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
113. Nonsteroidal anti-inflammatory drugs, short-chain fatty acids and reactive oxygen metabolism in human colorectal cancer cells
114. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc (Min/+) mice
115. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors
116. Meloxicam inhibits the growth of non-small cell lung cancer
117. Topical application of a selective cyclooxygenase inhibitor suppresses UVB-induced cutaneous inflammation
118. The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells
119. Genetic disruption of Cox1, as well as Cox2, reduces intestinal tumorigenesis in Min mice
120. Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents
121. 2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions
122. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus
123. Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
124. Selective inhibition of cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells
125. Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract
126. Prostanoid receptors: Structures, properties and functions
127. 2 receptor expression
128. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis
129. Inhibitory effect of a prostaglandin E receptor subtype EP1 selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice
130. 4
131. The effect of leukotriene B and selected HETE2 on the proliferation of colon cancer cells
132. Leukotriene B4 receptor: Cloning and intracellular signaling
133. 4 receptor, BLT2: A new therapeutic target in inflammation and immunological disorders
134. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion
135. 4 in acute renal ischemic-reperfusion injury
136. Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit
137. Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase
138. Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth
139. Altered inflammatory response in leukotriene-deficient mice
140. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute inflammatory responses
141. Induction of apoptosis by ubenimex (bestatin) in human non-small-cell lung cancer cell lines
142. The effect of ubenimex on N-methyl-N'-nitro-N-nitrosoguanidine-induced stomach tumor in rats
143. Review of ubenimex (bestatin): Clinical research
144. Eicosanoid regulation of angiogenesis: Role of endothelial arachidonate 12-lipoxygenase
145. Lipoxygenase inhibitors as potential cancer chemopreventives
146. 15-Lox-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells
147. Mucosal reactive oxygen species production in esophagitis and Barrett's esophagus
148. Reflux esophagitis in humans is a free radical event
149. Effects of β-carotene therapy on symptomatic, endoscopic and histologic parameters in patients with Barrett's esophagus
150. Mutagenic specificity of oxygen radicals produced by human leukemia cells
151. Many mutations in cancer
152. Effect of intravenous iron dextran on rheumatoid synovitis
153. Iron inhibits the nonspecific tumoricidal activity of macrophages
154. Body iron stores and risk of cancer
155. Cancer risk following primary hemochromatosis: A population-based cohort study in Denmark
156. 2 activation: Inhibition of protein tyrosine phosphatases and activation of protein kinases
157. 2-induced stimulation of mitogen-activated protein kinases (extracellular-signal-regulated kinase and c-Jun NH2-terminal kinase)
158. 2 dependence of diaphragm mitochondrial formation of reactive oxygen species
159. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation
160. 2 and the subsequent release of arachidonic acid, in signalling by rac for the generation of intracellular reactive oxygen species in rat-2 fibroblasts
161. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo
162. Genetic factors determine the contribution of leukotrienes to acute inflammatory responses
163. 2
164. 4 pathway to inflammation control
165. Feedback control of cyclooxygenase-2 expression through PPAR-γ